Alnylam Pharmaceuticals, Inc. (ALNY): Price and Financial Metrics


Alnylam Pharmaceuticals, Inc. (ALNY): $197.89

-3.35 (-1.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALNY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALNY POWR Grades

  • ALNY scores best on the Quality dimension, with a Quality rank ahead of 60.42% of US stocks.
  • The strongest trend for ALNY is in Growth, which has been heading down over the past 179 days.
  • ALNY ranks lowest in Stability; there it ranks in the 19th percentile.

ALNY Stock Summary

  • ALNY has a market capitalization of $24,024,516,049 -- more than approximately 91.71% of US stocks.
  • The capital turnover (annual revenue relative to shareholder's equity) for ALNY is 5.02 -- better than 91.22% of US stocks.
  • ALNY's price/sales ratio is 27.17; that's higher than the P/S ratio of 95.07% of US stocks.
  • If you're looking for stocks that are quantitatively similar to ALNYLAM PHARMACEUTICALS INC, a group of peers worth examining would be BGNE, STM, INSM, CYTK, and EA.
  • ALNY's SEC filings can be seen here. And to visit ALNYLAM PHARMACEUTICALS INC's official web site, go to www.alnylam.com.

ALNY Valuation Summary

  • In comparison to the median Healthcare stock, ALNY's price/earnings ratio is 225.51% lower, now standing at -24.6.
  • Over the past 223 months, ALNY's price/sales ratio has gone down 408.2.

Below are key valuation metrics over time for ALNY.

Stock Date P/S P/B P/E EV/EBIT
ALNY 2022-09-23 27.3 136.9 -24.6 -30.0
ALNY 2022-09-22 27.5 138.2 -24.8 -30.3
ALNY 2022-09-21 28.0 140.7 -25.3 -30.8
ALNY 2022-09-20 28.8 144.6 -25.9 -31.7
ALNY 2022-09-19 29.3 147.3 -26.4 -32.3
ALNY 2022-09-16 28.9 145.2 -26.1 -31.8

ALNY Growth Metrics

    Its 5 year revenue growth rate is now at 506.31%.
  • Its 5 year cash and equivalents growth rate is now at 141.6%.
  • The 4 year revenue growth rate now stands at 506.31%.
Over the past 49 months, ALNY's revenue has gone up $777,419,000.

The table below shows ALNY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 884.245 -578.189 -980.717
2022-03-31 879.98 -577.226 -892.874
2021-12-31 844.287 -641.693 -852.824
2021-09-30 749.314 -614.696 -837.904
2021-06-30 687.534 -590.986 -886.681
2021-03-31 570.943 -604.46 -876.351

ALNY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALNY has a Quality Grade of C, ranking ahead of 30.65% of graded US stocks.
  • ALNY's asset turnover comes in at 0.22 -- ranking 188th of 681 Pharmaceutical Products stocks.
  • QGEN, TXMD, and KMDA are the stocks whose asset turnover ratios are most correlated with ALNY.

The table below shows ALNY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.220 0.833 -0.249
2021-06-30 0.204 0.833 -0.267
2021-03-31 0.171 0.832 -0.272
2020-12-31 0.159 0.842 -0.308
2020-09-30 0.141 0.832 -0.372
2020-06-30 0.130 0.853 -0.416

ALNY Price Target

For more insight on analysts targets of ALNY, see our ALNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $184.16 Average Broker Recommendation 1.64 (Moderate Buy)

ALNY Stock Price Chart Interactive Chart >

Price chart for ALNY

ALNY Price/Volume Stats

Current price $197.89 52-week high $236.80
Prev. close $201.24 52-week low $117.58
Day low $195.19 Volume 200,768
Day high $201.62 Avg. volume 918,621
50-day MA $206.40 Dividend yield N/A
200-day MA $163.32 Market Cap 23.75B

Alnylam Pharmaceuticals, Inc. (ALNY) Company Bio


Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company was founded in 2002 and is based in Cambridge, Massachusetts.


ALNY Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNY Latest Social Stream


Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Axcella Health (AXLA), Alnylam Pharma (ALNY) and Cytokinetics (CYTK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axcella Health (AXLA – Research Report), Alnylam Pharma (ALNY – Research Report) and Cytokinetics (CYTK – Research Report). Axcella Health (AXLA) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Axcella Health today and set a price target of $10.00. The company's shares closed last Friday at $1.71, close to its 52-week low of $1.35. According to TipRanks.com, Arce is a 4-star analyst with an average return of -27.5% and a 18.4% success rate.

Howard Kim on TipRanks | October 3, 2022

Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY) and Alnylam Pharma (ALNY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY – Research Report) and Alnylam Pharma (ALNY – Research Report). Eli Lilly & Co (LLY) In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Eli Lilly & Co, with a price target of $396.00. The company's shares closed last Monday at $323.40, close to its 52-week high of $341.70. According to TipRanks.

Catie Powers on TipRanks | October 3, 2022

Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced results from exploratory endpoints and additional analyses from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The RNAi drug maintained “generally consistent” benefits in efficacy and quality of life across several prespecified subgroups at month 12, Alnylam announced. It also revealed more detail on a key miss, a composite secondary endpoint including all-cause mortality. The researc

Yahoo | October 3, 2022

Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting

CAMBRIDGE, Mass., September 30, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from exploratory endpoints and additional analyses of prespecified patient subgroups for the primary and secondary endpoints in the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The results were presented during a moderated pos

Yahoo | September 30, 2022

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Yahoo | September 22, 2022

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo N/A
3-mo 28.99%
6-mo 21.09%
1-year -0.23%
3-year 156.93%
5-year 61.35%
YTD 16.69%
2021 30.48%
2020 12.85%
2019 57.96%
2018 -42.61%
2017 239.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7636 seconds.